Diamond-Blackfan anemia

What is Diamond-Blackfan anemia?

Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that primarily affects red blood cell production. This condition typically manifests in infancy with severe anemia, often accompanied by physical abnormalities such as thumb defects and growth delays. DBA affects approximately 5-7 per million births worldwide, making it one of the rarer causes of congenital anemia. The condition results from mutations in genes responsible for ribosome function, the cellular machinery essential for protein synthesis.

Key statistics

Symptoms

Primary symptoms: Severe macrocytic anemia, growth retardation, thumb anomalies, short stature, heart defects, cleft palate

Diamond-Blackfan anemia presents with a constellation of symptoms that typically emerge in early infancy. The hallmark feature is severe macrocytic anemia, characterized by a critically low red blood cell count with abnormally large red blood cells. Affected infants often appear pale, weak, and lethargic, with poor feeding and failure to thrive.

Physical abnormalities occur in approximately 50% of patients and may include thumb malformations ranging from triphalangeal thumbs to complete thumb absence. Growth retardation is common, with many children falling below normal height and weight percentiles. Craniofacial abnormalities can include cleft lip or palate, micrognathia (small jaw), and distinctive facial features.

Submit Your Paper

Cardiac defects affect about 15% of patients, most commonly ventricular septal defects or coarctation of the aorta. Some individuals may develop kidney abnormalities, intellectual disabilities, or endocrine dysfunction. The severity and combination of symptoms varies significantly between patients, even within the same family.

Causes and risk factors

Diamond-Blackfan anemia is caused by mutations in genes encoding ribosomal proteins, the components responsible for protein synthesis within cells. Over 20 different genes have been identified as causes of DBA, with RPS26, RPS24, RPS17, RPL5, and RPS7 being among the most commonly affected. These mutations impair ribosome assembly and function, particularly affecting the production of red blood cells in the bone marrow.

The condition follows an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene is sufficient to cause the disease. Approximately 45% of cases are inherited from an affected parent, while 55% result from de novo (new) mutations occurring spontaneously. The risk factors are primarily genetic, with affected individuals having a 50% chance of passing the condition to each child.

Interestingly, the condition shows variable expressivity and incomplete penetrance, meaning that family members with the same mutation may have different symptoms or severity levels, and some carriers may remain unaffected.

Prevention

As Diamond-Blackfan anemia is a genetic condition, there is no way to prevent its occurrence. However, genetic counseling and testing play crucial roles in family planning for affected individuals and their relatives. Preimplantation genetic diagnosis (PGD) may be available for couples where one partner carries a known DBA mutation, allowing selection of unaffected embryos during in vitro fertilization.

Prenatal genetic testing through chorionic villus sampling or amniocentesis can identify affected pregnancies when a familial mutation is known. Carrier testing is not applicable since DBA follows a dominant inheritance pattern, but genetic testing can identify at-risk family members who may be presymptomatic or mildly affected.

Complications

Without appropriate treatment, Diamond-Blackfan anemia can lead to severe life-threatening complications. Untreated anemia may result in heart failure, growth arrest, and developmental delays. The chronic anemia can cause cardiomegaly (enlarged heart) and other cardiovascular complications.

Long-term complications include an increased risk of colorectal cancer, with studies showing a significantly higher incidence compared to the general population. Patients may also develop iron overload, particularly those requiring frequent blood transfusions, which can damage the heart, liver, and endocrine organs.

Steroid-related complications are common in treated patients and may include growth suppression, osteoporosis, cataracts, diabetes, hypertension, and increased susceptibility to infections. Bone marrow transplant complications, while less common, can include graft-versus-host disease and secondary malignancies.

Diagnosis

Diagnosing Diamond-Blackfan anemia requires a combination of clinical features, laboratory findings, and genetic testing. The diagnostic criteria include macrocytic anemia presenting before age one, reticulocytopenia (low immature red blood cell count), and normal or slightly reduced white blood cell and platelet counts.

Laboratory tests reveal elevated adenosine deaminase activity in red blood cells, a characteristic biochemical marker. Bone marrow examination typically shows selective reduction in red blood cell precursors with normal white cell and platelet lineages. Hemoglobin F (fetal hemoglobin) levels are often elevated.

Genetic testing can identify mutations in known DBA genes in approximately 70-75% of patients. The remaining cases likely involve mutations in undiscovered genes. Physical examination should assess for associated congenital anomalies, particularly thumb abnormalities and growth parameters.

Differential diagnosis includes other causes of congenital anemia such as transient erythroblastopenia of childhood, Fanconi anemia, and other inherited bone marrow failure syndromes.

Treatment

Treatment for Diamond-Blackfan anemia focuses on managing anemia and associated complications. Prednisolone is the first-line therapy, with approximately 80% of patients initially responding to corticosteroids. The typical starting dose is 2 mg/kg/day, gradually tapered to the lowest effective maintenance dose.

For patients who don’t respond to steroids or cannot tolerate them due to side effects, regular blood transfusions become necessary. Transfusion therapy requires concurrent iron chelation with deferasirox, deferoxamine, or deferiprone to prevent iron overload.

Hematopoietic stem cell transplantation offers the only curative treatment but is typically reserved for transfusion-dependent patients with suitable donors due to associated risks. Success rates are highest with matched sibling donors.

Emerging therapies include leucine supplementation, which has shown promise in improving anemia in some patients by enhancing ribosome biogenesis. Gene therapy approaches are under investigation but remain experimental.

Prognosis

The prognosis for Diamond-Blackfan anemia varies significantly depending on treatment response and associated complications. Patients who respond well to corticosteroids generally have better outcomes, with many achieving normal or near-normal life expectancy. However, long-term steroid use carries significant morbidity risks.

Transfusion-dependent patients face challenges related to iron overload and its complications, potentially affecting cardiac and hepatic function. With proper iron chelation therapy, many patients can maintain good quality of life for decades.

Successful bone marrow transplantation offers excellent long-term survival rates exceeding 80-90% in optimal candidates. The increased cancer risk, particularly colorectal cancer beginning in early adulthood, requires lifelong surveillance and affects long-term prognosis.

Overall survival has improved significantly with modern supportive care, though the condition requires lifelong medical management and monitoring.

Quality of life

Living with Diamond-Blackfan anemia requires ongoing medical care and lifestyle adaptations. Regular medical appointments for monitoring blood counts, assessing treatment effectiveness, and screening for complications are essential. Patients should maintain a balanced diet rich in folate and avoid iron supplements unless specifically prescribed.

Physical activity tolerance may be limited by anemia severity, but regular exercise within individual capabilities is encouraged to maintain cardiovascular health and bone density. Sleep quality may be affected by anemia-related fatigue, making good sleep hygiene practices important.

Mental health support is crucial, as chronic illness can impact psychological well-being. Many patients benefit from counseling, support groups, and connecting with other families affected by DBA. Educational accommodations may be necessary for children experiencing fatigue or steroid-related side effects.

Career and lifestyle choices may need consideration of medical needs, including access to healthcare and flexibility for medical appointments. Many patients live fulfilling lives with appropriate support and medical management.

Pregnancy and fertility

Diamond-Blackfan anemia can complicate pregnancy due to increased physiological demands on red blood cell production. Women with DBA require specialized obstetric care with close monitoring of hemoglobin levels and potential need for transfusion support during pregnancy.

Fertility may be affected by chronic illness and steroid therapy, though many patients conceive successfully. Genetic counseling is essential before conception to discuss the 50% risk of passing DBA to offspring and available reproductive options.

Medication management during pregnancy requires careful consideration, as corticosteroids may affect fetal development. Iron chelation therapy typically requires modification or discontinuation during pregnancy. Preconception planning with hematology and maternal-fetal medicine specialists optimizes outcomes.

Children

Children with Diamond-Blackfan anemia require pediatric hematology care and monitoring for growth and development. Growth retardation is common and may be exacerbated by steroid therapy, requiring endocrine evaluation and possible growth hormone therapy.

Educational support may be needed for children experiencing fatigue, frequent medical appointments, or steroid-related mood changes and concentration difficulties. School nurses should be informed about the condition and emergency protocols.

Immunizations should follow standard schedules with special attention to preventing infections in steroid-treated patients. Live vaccines may require timing adjustments based on immunosuppression levels.

Psychosocial support helps children and families cope with chronic illness challenges, including peer relationships and activity limitations.

When to see a doctor

Immediate medical attention is required for signs of severe anemia including extreme pallor, difficulty breathing, chest pain, dizziness, or heart palpitations. Fever in steroid-treated patients requires prompt evaluation due to increased infection risk.

Parents should seek urgent care for signs of iron overload complications such as abdominal pain, joint pain, or cardiac symptoms in transfusion-dependent patients. Any concerning changes in growth, development, or neurological function warrant medical evaluation.

Routine follow-up appointments are essential for monitoring treatment response, adjusting medications, and screening for complications including cancer surveillance beginning in early adulthood.

Regional context

Specific prevalence data for Diamond-Blackfan anemia in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited due to the rarity of the condition. The Global Medical Journal invites healthcare providers and researchers from these regions to contribute data on local prevalence, founder mutations, and healthcare access challenges for DBA patients.

Regional genetic studies could provide valuable insights into population-specific mutation patterns and help optimize diagnostic approaches for local populations.

Research and clinical trials

Current research focuses on understanding ribosomal biology, developing targeted therapies, and improving treatment outcomes. Gene therapy approaches using viral vectors to deliver functional copies of affected genes show promise in preclinical studies.

Clinical trials are investigating novel treatments including ribosome-targeting compounds, growth factors, and combination therapies. The EPAG DBA trial evaluated eltrombopag for thrombocytopenia, while studies of sotatercept explore erythroid maturation agents.

Patients can find current clinical trials through ClinicalTrials.gov using search terms “Diamond-Blackfan anemia” or “DBA.” The Diamond Blackfan Anemia Foundation maintains information about ongoing research opportunities and connects patients with investigators.

Frequently asked questions

Can Diamond-Blackfan anemia be cured?

Currently, bone marrow transplantation is the only curative treatment, but it carries significant risks and is typically reserved for severely affected patients with suitable donors. Most patients manage their condition with long-term medical therapy.

Will my child outgrow Diamond-Blackfan anemia?

DBA is a lifelong condition, though some patients may achieve transfusion independence or require less intensive treatment as they age. Spontaneous remission occurs in approximately 20% of patients, though the anemia may recur.

Is it safe to have children if I have DBA?

Many people with DBA have children successfully, though there is a 50% chance of passing the condition to each child. Genetic counseling and prenatal testing options can help inform family planning decisions.

How often will my child need blood transfusions?

Transfusion frequency varies greatly between patients. Some achieve remission with steroids and rarely need transfusions, while others require transfusions every 3-4 weeks. Treatment response determines individual needs.

What is the cancer risk with Diamond-Blackfan anemia?

DBA patients have an increased risk of colorectal cancer, with surveillance recommended starting at age 40 or earlier based on family history. The overall cancer risk is higher than the general population but varies among individuals.

Support and resources

Patient Organizations:
– Diamond Blackfan Anemia Foundation: www.dbafoundation.org
– DBA UK: www.dbauk.org.uk

International Resources:
– Orphanet: www.orpha.net
– National Organization for Rare Disorders (NORD): rarediseases.org
– European Rare Disease Organisation (EURORDIS): www.eurordis.org
– Global Genes: globalgenes.org

Medical Resources:
– GeneReviews (NCBI): www.ncbi.nlm.nih.gov/books/NBK7047/
– OMIM Database: www.omim.org

Related conditions

– Fanconi anemia
– Shwachman-Diamond syndrome
– Dyskeratosis congenita
– Congenital dyserythropoietic anemia
– Transient erythroblastopenia of childhood

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.